Salute e Benessere

NOTICE OF EXERCISE OF MAKE WHOLE CALL OPTION

NOTICE OF EXERCISE OF MAKE WHOLE CALL OPTIONMAXIMA GRUPE, UAB (the "Issuer")1€240,000,000 6.250 per cent. Notes due 2027 (the "Notes")(ISIN: XS2485155464) (Common Code: 248515546) 10 October 2025We refer to the terms and conditions of the Notes (the " Conditions "). Capitalised terms used in this notice that are not otherwise defined have the meaning given to them in the Conditions.Pursuant to Condition 6(e) ( Redemption at the Option of the Issuer (Make Whole) )…

Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has purchased an additional $500,000 worth of Ethereum (ETH), bringing its total investment in ETH to $1.5 million.This acquisition was executed pursuant to Cosmos Health’s previously announced $300 million digital assets facility, which is part of the Company’s broader strategic initiative to diversify its balance sheet and...

Croma-Pharma GmbH Enters Strategic Distribution Partnership with Renellence in…

Under the agreement, Renellence will distribute the MDR-approved (Medical Device Regulation) hyaluronic acid filler range Croma saypha® in Canada, further expanding access to Croma's science-driven, high-quality aesthetic solutions. The partnership reflects a shared commitment to innovation, excellence, and customer-focused service, laying the foundation for sustainable long-term growth. Under the agreement, Renellence will distribute the MDR-approved (Medical Device Regulation) hyaluronic…

NTG Nordic Transport Group A/S - Q3 2025 Conference Call

NTG Nordic Transport Group A/S – Q3 2025 Conference Call We expect to release the Q3 2025 interim results of NTG Nordic Transport Group on the evening of November 10, 2025. A webcast and conference call will be held in the morning of November 11, 2025, at 10:00 am CET. At the call, Group CEO Mathias Jensen-Vinstrup and Group CFO Christian D. Jakobsen will present the Q3 2025 Interim Financial Report. The presentation will be followed by a Q&A session.Date:November 11, 2025Time:...

Berlin Heals Holding AG Successfully Completes Enrollment in Phase I of the…

"Completing enrollment in under 6 months since implanting our first patient marks a pivotal moment for the company and reflects the degree of unmet need we are hearing from people living with Heart Failure," said Berlin Heals Holding Chief Executive OfficerJohn Brumfield. "We are very grateful to the patients, their families and the trial investigators for their enthusiasm and look forward to sharing topline results from the Phase I study next year." "Based on results…

SKF to publish Q3 report on 29 October

To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers:Link to web event: https://www.investis-live.com/skf/68c40e612728d2001df6538b/jnxer Sweden: +46 8 5051 0031 UK / International: +44 207 107 0613 To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers: Link to web event:https://www.investis-live.com/skf/68c40e612728d2001df6538b/jnxer Sweden : +46 8 5051 0031UK /…

Idorsia successfully completes an upsized offering of shares – funding the…

Ad hoc announcement pursuant to Art. 53 LR Idorsia successfully completes the offering of 16.4 million new and treasury shares – upsized from 15 million shares – through an accelerated bookbuilding process with gross proceeds of CHF 65.6 million Allschwil, Switzerland – October 10, 2025Idorsia Ltd (SIX: IDIA, “Idorsia”) announces that it has successfully raised CHF 65.6 million through the placement of 16.4 million registered shares (the “Offer Shares”) at a placement price of CHF 4...

NeuroVigil’s iBrain™ in TIME’s “Best Inventions of 2025”

SAN FRANCISCO and WATERLOO, Ontario and MONTREAL and LEIPZIG, Germany, Oct.09, 2025(GLOBE NEWSWIRE) -- TIME has announced today that Silicon Valley-based Neurotechnology Powerhouse NeuroVigil’s iBrain™ had been selected by its editors as one ofThe Best Inventions of 2025.The new ultra-small device, the size of two quarters, has twice the battery life of the previous design, four times more channels, and has sixteen different endpoints, enabling the AI-based hunt for biomarkers related...

Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with…

Platinum-Resistant Ovarian Cancer Market Summary Platinum-Resistant Ovarian Cancer Market Summary Discover the platinum-resistant ovarian cancer new treatment @New Treatments for Platinum-Resistant Ovarian Cancer Key Factors Driving the Growth of the Platinum-Resistant Ovarian Cancer Market Rising Ovarian Cancer Incidence In 2024, in the 7MM, there were around 61K incident cases of ovarian cancer. Ovarian cancer cases are increasing, and long-term projections show...

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in…

Built on Alamar's proprietary NULISA™ platform, the NULISAqpcr BD-pTau217 Assay delivers unprecedented sensitivity and specificity from non-invasive sample types such as plasma, serum and dried blood spots. The research assay's direct measurement of CNS-derived pTau217 without the need for cerebrospinal fluid (CSF) collection or PET imaging removes existing barriers to widespread adoption in population-based studies or longitudinal clinical trials. Built on Alamar's proprietary NULISA™...

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology…

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history –– Improvements in overall clinical status at 3 years in the open-label extension studie sreported by clinicians and caregivers in 95% of patients treated with zorevunersen – CAMBRIDGE, Mass. and BEDFORD, Mass., Oct.09, 2025(GLOBE NEWSWIRE) --Biogen Inc...

Endo Announces Nine New and Modified Presentations at the Sexual Medicine…

The nine new and modified Endo-sponsored and Endo-supported presentations are below: The nine new and modified Endo-sponsored and Endo-supported presentations are below: Sponsored by Endo: Investigator-Initiated Research: About Peyronie's DiseasePeyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy. 1 It is estimated that PD can affect as many as 1...

Procedure of the Annual General Meeting

ANNOUNCEMENT NO. 2949 October 2025Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter.At the Annual General Meeting, the Board of Directors' report on the company's activities during the past year was presented, the annual report for 2024/25 was approved, and the Board of Directors and the Executive Board were granted discharge.The Annual General Meeting approved the...

Atelier Expressions announces the acquisition of French porcelain manufacturer…

'I have always admired JL Coquet's creations, which reflect a timeless heritage and impeccable craftsmanship,' says Tara S. Venu, Executive Director of Atelier Expressions. "We are excited about the opportunities offered by this acquisition. The spirit of JL Coquet is perfectly in line with our ambition to bring international recognition to companies that embody exceptional quality and craftsmanship." 'I have always admired JL Coquet's creations, which reflect a timeless heritage…

XRlabs SIM Named to TIME Best Inventions 2025

"This recognition by TIME is a validation of our core mission: to redefine the surgical standards of care," said Dr. Ali Haddad, Founder and CEO of XRlabs and practicing neurosurgeon. "As a surgeon-founder, I built XRlabs SIM, our first product, to solve a fundamental unmet need: the lack of intuitive, integrated deep vision that prevents surgical knowledge from scaling globally. XRlabs SIM delivers a new layer of precision and confidence to surgeons, accelerating the…

Oxurion provides an update related to its investment strategy in digital assets

Leuven, BELGIUM, October 9, 2025, 6:00 PM – Oxurion NV (Euronext Brussels: OXUR) announces today that the completion of the new financing aimed at investing in digital assets (Bitcoin and Ethereum), originally scheduled to close on September 25, 2025, is still in progress. Administrative and compliance-related procedures (notably KYC/AML checks)…

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…

Disclosure of Share Capital and Voting Rights Outstandingas of September 30, 2025(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (October 9, 2025 - 6:00 pm)– As of September 30, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks...

Oxurion geeft een update met betrekking tot de strategie voor investering in…

Leuven, BELGIË, 9 oktober 2025, 18u00 – Oxurion NV (Euronext Brussel: OXUR) kondigt vandaag aan dat de afronding van de nieuwe financiering gericht op investeringen in digitale activa (Bitcoin en Ethereum), waarvan de closing oorspronkelijk gepland was op 25 september 2025, nog in voorbereiding is. De administratieve en compliance-gerelateerde…

Coloplast interim CEO Lars Rasmussen will step down from the Board at the…

Announcement no. 09/2025 Inside information Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting Coloplast interim CEO Lars Rasmussen has today informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. “On behalf of the Board, I want to thank Lars for his unwavering dedication to Coloplast. Through his commitment to the company for...

Idorsia launches an offering of registered shares – to fund the company to…

Ad hoc announcement pursuant to Art. 53 LR Idorsia launches an offering of approximately 15 million newly issued and treasury shares through an accelerated bookbuilding process, to extend operating cash runway into 2028The net proceeds of this offering will fund Idorsia’s disciplined, phased investment in accelerating QUVIVIQ’s commercial trajectory toward commercial profitability in 2026 and advancing a de-risked, science-driven pipelineAllschwil, Switzerland – October 9, 2025...

OUTCOMES4ME NAMED TO TIME'S LIST OF THE BEST INVENTIONS OF 2025

"We are honored that TIME recognizes Outcomes4Me for 'demystifying cancer care' and the important work we are doing to improve health outcomes for all people living with cancer," Dr. Said continued. "We are honored that TIME recognizes Outcomes4Me for 'demystifying cancer care' and the important work we are doing to improve health outcomes for all people living with cancer," Dr. Said continued. To compile this year's Best Inventions list, which features 300 extraordinary…

Endoscopy Procedures Market to Reach $617.8 billion, Globally, by 2034 at 5.5%…

Endoscopy can help diagnose conditions such as ulcers, tumors, infections, and inflammation, and it is also used for performing biopsies, removing polyps, or treating bleeding. It offers benefits such as reduced recovery time, less pain, and lower risk compared to traditional surgery, as endoscopy typically involves small incisions or natural body openings. Endoscopic procedures are usually performed on an outpatient basis and are guided by real-time imaging to ensure precision and safety. ...

Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI…

Harry Robb, Principal at Lifespan Vision Ventures, said "We are thrilled to see Algen Biotechnologies achieve this important milestone. The team has built a truly differentiated platform that integrates CRISPR-based functional screening with advanced AI analytics to uncover disease-relevant biology at scale. This collaboration with AstraZeneca underscores the strength of Algen's technology and its potential to transform drug discovery." Harry Robb, Principal at Lifespan Vision…

Softgel Capsules Market Size to Reach US$ 14.1 Billion by 2032, Growing at 6.3%…

Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/softgels-capsules-market Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/softgels-capsules-market Browse in-depth TOC on "Softgel Capsules Market" 54 – Tables 42 – Figures 180 – Pages Rising Demand for Personalized...

Altri Comunicati